Quick Answer
ABVC BIOPHARMA, INC. reported Total Revenue of $509.6 thousand for fiscal year 2024.
ABVC BIOPHARMA, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | $509.6K +234.3% |
$152.4K -84.3% |
$969.8K +172.6% |
$355.8K -26.3% |
$483.0K -31.2% |
| Net Income | -$7.91M -61.3% |
-$4.90M +37.0% |
-$7.79M +52.6% |
-$16.42M -27.9% |
-$12.84M -21.2% |
-$10.59M -169.3% |
| Diluted EPS | -$0.39 +7.1% |
-$0.42 +76.7% |
-$1.80 +65.3% |
-$5.19 -917.6% |
-$0.51 | — |
| Total Assets | $21.06M +179.3% |
$7.54M -3.1% |
$7.78M -18.7% |
$9.58M -30.1% |
$13.70M +18.0% |
$11.61M +67.5% |
| Cash and Equivalents | $681.5K +174.4% |
$248.4K +312.9% |
$60.2K -29.4% |
$85.3K -98.5% |
$5.83M +36.4% |
$4.27M +2861.4% |
| Stockholders Equity | $11.11M +806.2% |
$1.23M -21.1% |
$1.55M -49.8% |
$3.10M -65.0% |
$8.84M +157.2% |
$3.44M +2377.6% |
| R&D Expense | $121.1K -32.5% |
$179.3K -83.1% |
$1.06M -60.5% |
$2.69M +168.3% |
$1.00M +82.6% |
$549.7K -47.6% |
| Operating Income | -$7.15M -52.0% |
-$4.71M +30.5% |
-$6.77M +55.2% |
-$15.11M -29.1% |
-$11.71M -37.6% |
-$8.51M -145.9% |
| Gross Profit | — | $508.8K +440.1% |
-$149.6K -121.9% |
$683.4K +94.9% |
$350.7K -24.5% |
$464.3K -31.9% |
| Shares Outstanding | 25.05M +80.6% |
13.87M +74.7% |
7.94M +141.6% |
3.29M -86.5% |
24.42M +0.0% |
24.42M +25.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $796.0K | +104.5% | +104.5% |
| Net Income | September 30, 2025 | -$1.25M | -215.8% | +44.8% |
| Diluted EPS | September 30, 2025 | -$0.05 | -66.7% | +61.5% |
| Total Assets | September 30, 2025 | $21.18M | +172.3% | +30.4% |
| Cash and Equivalents | September 30, 2025 | $192.1K | +39.8% | -50.5% |
| Long-Term Debt | September 30, 2020 | $124.4K | — | +0.0% |
| Stockholders Equity | September 30, 2025 | $12.06M | +634.3% | +71.9% |
| R&D Expense | September 30, 2025 | $29.9K | -21.0% | -10.2% |
| Operating Income | September 30, 2025 | -$1.17M | -286.5% | +49.1% |
| Gross Profit | September 30, 2025 | $796.0K | +104.6% | +104.6% |
| Shares Outstanding | September 30, 2025 | 24.19M | +90.3% | +23.8% |
- ABVC BIOPHARMA, INC. reported Total Revenue of $509.6 thousand for fiscal year 2024.
- ABVC BIOPHARMA, INC. showed an increase of +234.3% in Total Revenue compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported Net Income of -$7.91 million for fiscal year 2025.
- ABVC BIOPHARMA, INC. showed a decrease of -61.3% in Net Income compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported Diluted EPS of $0.39 per share (loss) for fiscal year 2025.
- ABVC BIOPHARMA, INC. showed an increase of +7.1% in Diluted EPS compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported Total Assets of $21.06 million for fiscal year 2025.
- ABVC BIOPHARMA, INC. showed an increase of +179.3% in Total Assets compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported Cash and Equivalents of $681.5 thousand for fiscal year 2025.
- ABVC BIOPHARMA, INC. showed an increase of +174.4% in Cash and Equivalents compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported Stockholders Equity of $11.11 million for fiscal year 2025.
- ABVC BIOPHARMA, INC. showed an increase of +806.2% in Stockholders Equity compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported R&D Expense of $121.1 thousand for fiscal year 2025.
- ABVC BIOPHARMA, INC. showed a decrease of -32.5% in R&D Expense compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported Operating Income of -$7.15 million for fiscal year 2025.
- ABVC BIOPHARMA, INC. showed a decrease of -52.0% in Operating Income compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported Gross Profit of $508.8 thousand for fiscal year 2024.
- ABVC BIOPHARMA, INC. showed an increase of +440.1% in Gross Profit compared to the prior fiscal year.
- ABVC BIOPHARMA, INC. reported Shares Outstanding of 25.05 million shares for fiscal year 2025.
- ABVC BIOPHARMA, INC. showed an increase of +80.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: